Active, not recruitingPhase 2NCT06033092
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
Studying Ataxia-telangiectasia variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Institute of Oncology
- Principal Investigator
- Bernardo Bonanni, MDIstituto Europeo di Oncologia
- Intervention
- Tamoxifen 10 mg Tablet(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18-70 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (4)
- E.O. Galliera, Genoa, Italy
- Istituto Europeo di Oncologia, Milan, Italy
- Istituto Nazionale Tumori G. Pascale, Naples, Italy
- Istituto Oncologico Veneto, Padua, Italy
Collaborators
Ente Ospedaliero Ospedali Galliera · Istituto Oncologico Veneto IRCCS · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06033092 on ClinicalTrials.govOther trials for Ataxia-telangiectasia variant
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07224308Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mmThe Levine Center for Plastic Surgery
- ACTIVE NOT RECRUITINGPHASE2NCT04030559Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsMarc Dall'Era, MD
- RECRUITINGNCT05129605Prostate Cancer Genetic Risk Evaluation and Screening StudyMassachusetts General Hospital